UNITED STATES
SECURITIES EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________________________
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)
LIGAND PHARMACEUTICALS INCORPORATED
-----------------------------------
(Name of Issuer)
Common Stock, $.001 par value per share
---------------------------------------------------
(Title of Class of Securities)
53220K207
-----------------------------
(CUSIP Number)
December 31, 2005
-----------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[ X ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
Continued on following pages
Page 1 of 11 Pages
Exhibit Index: Page 9
SCHEDULE 13G
CUSIP No.: 53220K207 Page 2 of 11 Pages
...............................................................................
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
GLENVIEW CAPITAL MANAGEMENT, LLC
...............................................................................
2. Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ]
...............................................................................
3. SEC Use Only
...............................................................................
4. Citizenship or Place of Organization
Delaware
...............................................................................
Number of 5. Sole Voting Power None
Shares ................................................................
Beneficially 6. Shared Voting Power 6,906,000
Owned by Each ................................................................
Reporting 7. Sole Dispositive Power None
Person With ................................................................
8. Shared Dispositive Power 6,906,000
...............................................................................
9. Aggregate Amount Beneficially Owned by Each Reporting Person
6,906,000
...............................................................................
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
[ ]
...............................................................................
11. Percent of Class Represented by Amount in Row (9)
9.3% based on 74,131,283 shares outstanding as of December 15, 2004.
...............................................................................
12. Type of Reporting Person:
OO
SCHEDULE 13G
CUSIP No.: 53220K207 Page 3 of 11 Pages
...............................................................................
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
GLENVIEW CAPITAL GP, LLC
...............................................................................
2. Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ]
...............................................................................
3. SEC Use Only
...............................................................................
4. Citizenship or Place of Organization
Delaware
...............................................................................
Number of 5. Sole Voting Power None
Shares ................................................................
Beneficially 6. Shared Voting Power 6,906,000
Owned by Each ................................................................
Reporting 7. Sole Dispositive Power None
Person With ................................................................
8. Shared Dispositive Power 6,906,000
...............................................................................
9. Aggregate Amount Beneficially Owned by Each Reporting Person
6,906,000
...............................................................................
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
[ ]
...............................................................................
11. Percent of Class Represented by Amount in Row (9)
9.3% based on 74,131,283 shares outstanding as of December 15, 2004.
...............................................................................
12. Type of Reporting Person:
OO
SCHEDULE 13G
CUSIP No.: 53220K207 Page 4 of 11 Pages
...............................................................................
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
GLENVIEW CAPITAL MASTER FUND, LTD.
...............................................................................
2. Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ]
...............................................................................
3. SEC Use Only
...............................................................................
4. Citizenship or Place of Organization
Cayman Islands, British West Indies
...............................................................................
Number of 5. Sole Voting Power None
Shares ................................................................
Beneficially 6. Shared Voting Power 3,980,843
Owned by Each ................................................................
Reporting 7. Sole Dispositive Power None
Person With ................................................................
8. Shared Dispositive Power 3,980,843
...............................................................................
9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,980,843
...............................................................................
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
[X]
...............................................................................
11. Percent of Class Represented by Amount in Row (9)
5.4% based on 74,131,283 shares outstanding as of December 15, 2004.
...............................................................................
12. Type of Reporting Person:
IA
SCHEDULE 13G
CUSIP No.: 53220K207 Page 5 of 11 Pages
...............................................................................
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
LAWRENCE M. ROBBINS
...............................................................................
2. Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ]
...............................................................................
3. SEC Use Only
...............................................................................
4. Citizenship or Place of Organization
United States of America
...............................................................................
Number of 5. Sole Voting Power None
Shares ................................................................
Beneficially 6. Shared Voting Power 6,906,000
Owned by Each ................................................................
Reporting 7. Sole Dispositive Power None
Person With ................................................................
8. Shared Dispositive Power 6,906,000
...............................................................................
9. Aggregate Amount Beneficially Owned by Each Reporting Person
6,906,000
...............................................................................
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
[ ]
...............................................................................
11. Percent of Class Represented by Amount in Row (9)
9.3% based on 74,131,283 shares outstanding as of December 15, 2004.
...............................................................................
12. Type of Reporting Person:
IA
Page 6 of 11 Pages
Item 1(a). Name of Issuer:
Ligand Pharmaceuticals Incorporated (the "Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
10275 Science Center Drive, San Diego, CA 92121-1117.
Item 2(a). Name of Person Filing
This Statement is filed on behalf of each of the following
persons (collectively, the "Reporting Persons"):
i) Glenview Capital Management, LLC ("Glenview Capital
Management");
ii) Glenview Capital GP, LLC ("Glenview Capital GP");
iii) Glenview Capital Master Fund, Ltd. ("Glenview Capital
Master Fund); and
iv) Lawrence M. Robbins ("Mr. Robbins").
This Statement relates to Shares (as defined herein) held for
the accounts of Glenview Capital Partners, L.P., a Delaware limited
partnership ("Glenview Capital Partners"), Glenview Institutional Partners,
L.P., a Delaware limited partnership ("Glenview Institutional Partners"), GCM
Little Arbor Master Fund, Ltd., a Cayman Islands exempted company ("GCM Little
Arbor Master Fund"), GCM Little Arbor Institutional Partners, L.P., a Delaware
limited partnership ("GCM Little Arbor Institutional Partners"), and GCM
Little Arbor Partners, L.P., a Delaware limited partnership ("GCM Little Arbor
Partners").
Glenview Capital Management serves as investment manager to
each of Glenview Capital Partners, Glenview Institutional Partners, Glenview
Capital Master Fund, GCM Little Arbor Master Fund, GCM Little Arbor
Institutional Partners, and GCM Little Arbor Partners. In such capacity,
Glenview Capital Management may be deemed to have voting and dispositive power
over the Shares held for the accounts of each of Glenview Capital Partners,
Glenview Institutional Partners, Glenview Capital Master Fund, GCM Little
Arbor Master Fund, GCM Little Arbor Institutional Partners, and GCM Little
Arbor Partners. Glenview Capital GP is the general partner of Glenview Capital
Partners, Glenview Institutional Partners, GCM Little Arbor Institutional
Partners and GCM Little Arbor Partners. Glenview Capital GP also serves as the
sponsor of the Glenview Capital Master Fund and the GCM Little Arbor Master
Fund. In such capacities, Glenview Capital GP may be deemed to have voting and
dispositive power over the Shares held for the accounts of each of Glenview
Capital Partners, Glenview Institutional Partners, Glenview Capital Master
Fund, GCM Little Arbor Master Fund, GCM Little Arbor Institutional Partners,
and GCM Little Arbor Partners. Mr. Robbins is the Chief Executive Officer of
Glenview Capital Management and Glenview Capital GP.
Item 2(b). Address of Principal Business Office or, if None, Residence
The address of the principal business office of each of
Glenview Capital Management, Glenview Capital GP, and Mr. Robbins is 399 Park
Avenue, Floor 39, New York, New York 10022. The address of the principal
business office of Glenview Capital Master Fund is Harbour Centre, North
Church Street, P.O. Box 8966T, George Town, Grand Cayman, Cayman Islands,
British West Indies.
Page 7 of 11 Pages
Item 2(c). Citizenship
i) Glenview Capital Management is a Delaware limited
liability company;
ii) Glenview Capital GP is a Delaware limited liability
company;
iii) Glenview Capital Master Fund is a Cayman Islands
exempted company; and
iv) Mr. Robbins is a citizen of the United States of
America.
Item 2(d). Title of Class of Securities:
Common Stock, $0.001 par value per share (the "Shares")
Item 2(e). CUSIP Number:
53220K207
Item 3. If This Statement is Filed Pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c),Check Whether the Person Filing is a:
This Item 3 is not applicable.
Item 4. Ownership:
Item 4(a). Amount Beneficially Owned:
(i) As of February 14, 2006, each of Glenview Capital
Management, Glenview Capital GP and Mr. Robbins may be deemed to be the
beneficial owner of 6,906,000 Shares. This amount consists of: (A) 346,013
Shares held for the account of Glenview Capital Partners; (B) 3,980,843 Shares
held for the account of Glenview Capital Master Fund; (C) 1,939,844 Shares
held for the account of Glenview Institutional Partners; (D) 498,902 Shares
held for the account of GCM Little Arbor Master Fund, (E) 131,856 Shares held
for the account of GCM Little Arbor Institutional Partners, and (F) 8,542
Shares held for the account of GCM Little Arbor Partners.
(ii) As of February 14, 2006, Glenview Capital Master Fund may
be deemed to be the beneficial owner of 3,980,843 Shares. This amount consists
of 3,980,843 Shares held for its account.
Item 4(b) Percent of Class:
(i) The number of Shares of which each of Glenview Capital
Management, Glenview Capital GP and Mr. Robbins may be deemed to be the
beneficial owner constitutes approximately 9.3% of the total number of Shares
outstanding (based upon information provided by the Issuer in its most
recently-filed proxy statement, there were approximately 74,131,283 shares
outstanding as of December 15, 2004).
(ii) The number of Shares of which Glenview Capital Master
Fund may be deemed to be the beneficial owner constitutes approximately 5.4%
of the total number of Shares outstanding (based upon information provided by
the Issuer in its most recently-filed proxy statement, there were
approximately 74,131,283 shares outstanding as of December 15, 2004).
Page 8 of 11 Pages
Item 4(c) Number of Shares of which such person has:
Glenview Capital Management, Glenview Capital GP, and Mr. Robbins:
------------------------------------------------------------------
(i) Sole power to vote or direct the vote: 0
(ii) Shared power to vote or direct the vote: 6,906,000
(iii) Sole power to dispose or direct the disposition of: 0
(iv) Shared power to dispose or direct the disposition of: 6,906,000
Glenview Capital Master Fund:
-----------------------------
(i) Sole power to vote or direct the vote: 0
(ii) Shared power to vote or direct the vote: 3,980,843
(iii) Sole power to dispose or direct the disposition of: 0
(iv) Shared power to dispose or direct the disposition of: 3,980,843
Item 5. Ownership of Five Percent or Less of a Class:
This Item 5 is not applicable
Item 6. Ownership of More than Five Percent on Behalf of Another
Person:
This Item 6 is not applicable
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company:
See disclosure in Item 2 hereof.
Item 8. Identification and Classification of Members of the Group:
This Item 8 is not applicable.
Item 9. Notice of Dissolution of Group:
This Item 9 is not applicable.
Item 10. Certification:
By signing below each of the Reporting Persons certifies that,
to the best of their knowledge and belief, the securities referred to above
were not acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any
transaction having that purpose or effect.
Page 9 of 11 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: February 14, 2006 GLENVIEW CAPITAL MANAGEMENT, LLC
By: /s/ Lawrence M. Robbins
-----------------------------
Name: Lawrence M. Robbins
Title: Chief Executive Officer
Date: February 14, 2006 GLENVIEW CAPITAL GP, LLC
By: /s/ Lawrence M. Robbins
----------------------------
Name: Lawrence M. Robbins
Title: Chief Executive Officer
Date: February 14, 2006 GLENVIEW CAPITAL MASTER FUND, LTD.
By: Glenview Capital Management, LLC
As Investment Manager
By: /s/ Lawrence M. Robbins
----------------------------
Name: Lawrence M. Robbins
Title: Chief Executive Officer
Date: February 14, 2006 LAWRENCE M. ROBBINS
/s/ Lawrence M. Robbins
-----------------------
Page 10 of 11 Pages
EXHIBIT INDEX
Ex. Page No.
--- --------
B. Joint Filing Agreement, dated February 14, 2006 by and among
Glenview Capital Management, LLC, Glenview Capital GP, LLC,
Glenview Capital Master Fund, Ltd. and Lawrence M.
Robbins..................................................... 11
Page 11 of 11 Pages
EXHIBIT B
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13G,
Amendment No. 1 with respect to the Common Stock of Ligand Pharmaceuticals
Incorporated dated as of February 14, 2006 is, and any amendments thereto
(including amendments on Schedule 13D) signed by each of the undersigned shall
be, filed on behalf of each of us pursuant to and in accordance with the
provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as
amended.
Date: February 14, 2006 GLENVIEW CAPITAL MANAGEMENT, LLC
By: /s/ Lawrence M. Robbins
-----------------------------
Name: Lawrence M. Robbins
Title: Chief Executive Officer
Date: February 14, 2006 GLENVIEW CAPITAL GP, LLC
By: /s/ Lawrence M. Robbins
----------------------------
Name: Lawrence M. Robbins
Title: Chief Executive Officer
Date: February 14, 2006 GLENVIEW CAPITAL MASTER FUND, LTD.
By: Glenview Capital Management, LLC
As Investment Manager
By: /s/ Lawrence M. Robbins
----------------------------
Name: Lawrence M. Robbins
Title: Chief Executive Officer
Date: February 14, 2006 LAWRENCE M. ROBBINS
/s/ Lawrence M. Robbins
----------------------------